Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

Autor:	M. Gramatzki, J.T. Fischer, I.-M. von Broen, R. Henke, J. Oertel, E. Schäfer, J. Selbach, R. Coldewey, H. Wagner, R. Hein, H. J. Braun, Deicher H, D. Peest, M. Planker, C. Tirier, R. Leo, H. Bartels, W. Stenzinger, C.R. Meier, E. Schumacher, L. Hoffmann, M. Stennes, K. Schumacher, E. D. Kreuser, W. D. Maier, J. Wysk, R. Bartl, H. J. Weh, H.M. Reinhold
Rok vydání:	1990
Předmět:	Oncology Melphalan Cancer Research medicine.medical_specialty Vincristine business.industry Induction chemotherapy Hematology medicine.disease Prednisone Interferon Internal medicine Multicenter trial medicine business Dexamethasone Multiple myeloma medicine.drug
Zdroj:	Oncology Research and Treatment. 13:458-460
ISSN:	2296-5262 2296-5270
Popis:	277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observat
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::450d7fe7266909265fbcef22491e1292 https://doi.org/10.1159/000216820 Zobrazit plný text záznamu